Retatrutide
Research highlights
- ✓Simultaneous GLP-1, GIP & glucagon receptor activation
- ✓May offer greater metabolic efficacy than dual agonists in studies
- ✓May support fat-mass, appetite-regulation & energy-expenditure research
- ✓Extended research window with favourable pharmacokinetic profile
Read Carl's plain-English guide: Retatrutide on Peptide Carl ›
What is Retatrutide?
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. This tri-agonism makes it one of the most potent metabolic research compounds currently studied.
How does it compare to Tirzepatide?
Tirzepatide targets GLP-1 and GIP only. Retatrutide adds glucagon receptor activation, which may drive greater energy expenditure — it stood out significantly in Phase 2 trials.
What purity is guaranteed?
Where we hold an independent Janoshik report for a compound we publish it in full - batch number, purity and a verification key you can check against the lab yourself. Where we do not hold one the product is marked research grade and we say so, rather than claim a report we cannot produce.
Is there a minimum order?
No minimum — order as little as a single vial. We're here to support research at every scale.
Retatrutide, explained
The short version: Retatrutide is Eli Lilly's "triple agonist": one peptide that activates three hormone receptors (GLP-1, GIP and glucagon) where tirzepatide hits two and semaglutide hits one. It has now passed several phase 3 trials, but it is not an approved medicine yet.
What it is
Retatrutide (Lilly's code name was LY3437943) is a single peptide built to switch on the GLP-1 and GIP receptors, the same pair tirzepatide targets, plus a third: the glucagon receptor. Glucagon is usually thought of as the hormone that raises blood sugar, but it also pushes the body to burn energy, which is why researchers wanted it in the mix.
Why three receptors
The idea is that GLP-1 and GIP turn appetite down while the glucagon arm turns energy use up. Whether the third receptor adds as much as it seems to in trials, and at what cost, is exactly what the large trials are there to answer.
| Trial | When | Who | Result |
|---|---|---|---|
| Phase 2 | 2023 | Adults with obesity or overweight | 24.2% at 48 weeks |
| TRIUMPH-4 | Dec 2025 | Obesity with knee osteoarthritis | 28.7% at 68 weeks |
| TRIUMPH-2 | Jul 2026 | Obesity or overweight with type 2 diabetes | Up to 20.8% at 80 weeks |
| TRIUMPH-3 | Jul 2026 | Severe obesity with heart disease | Up to 22.6% at 80 weeks |
What the trials found
The phase 2 trial (New England Journal of Medicine, 2023) reported average weight loss of 24.2% after 48 weeks at the highest dose tested, against 2.1% on placebo.
Phase 3 followed. TRIUMPH-4 (December 2025), in people with obesity and knee osteoarthritis, reported 28.7% average weight loss at 68 weeks at the highest dose, along with a large drop in knee pain scores. TRIUMPH-2 and TRIUMPH-3 (July 2026) reported up to 20.8% and 22.6% at 80 weeks. Lilly plans to file for approval in early 2027.
Where the evidence stops
Every one of those numbers comes from Lilly's own pharmaceutical-grade drug, in supervised trials, in chosen groups of people. Until a regulator has reviewed the full data, nobody outside those trials knows the complete safety picture. Research-grade material is not the trial drug, and the trial results say nothing about what it will do.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water goes in, it belongs in the fridge. Our reconstitution and storage guide covers the details, and the calculator does the maths.
Three receptors and the biggest trial numbers in the field so far. Still a medicine in waiting, not an approved one.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered Retatrutide
3 reviews from orders that included Retatrutide. Reviews are of the whole order: service, delivery and what arrived.
★★★★★
It was my 1st order. Everything went smooth, fantastic, fabulous!!!!! Received my vials 3days after placing the order. Asked lots of questions and received answers within minutes. Great awesome service!!! Will definitely order again. Thanks so much. Keep it up.
Lila J. · 8 Oct 2026
★★★★★
Left a rating, no comment.
Sarel · 27 Sep 2026
★★★★
Package was delivered and I received the correct goods
Sarel M. · 26 Sep 2026
★ 4.8 across all 19 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
+ GH-Axis entry — CJC-1295 + Ipamorelin
The same pairing in a single vial. Half the total peptide of the full stack below, and the cheaper way in.
+ Glutathione
The compound most often researched alongside a metabolic protocol.
+ AOD-9604
Filed in the same research area as the compound you are viewing.
+ GH-Axis — CJC-1295 + Ipamorelin
The GHRH + GHRP pairing most commonly researched alongside a GLP-1 protocol.
+ MOTS-c
A mitochondrial-derived peptide commonly researched alongside GLP-1 protocols.
+ Tesamorelin
A GHRH analogue often researched in GLP-1 body-composition work.
+ GHK-Cu
A copper peptide researched for skin & tissue alongside GLP-1 protocols.
+ NAD+
A cellular-energy & longevity-research staple paired with GLP-1 protocols.
